VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Aug 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-08-03

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-03	Common Stock	M	4250	$109.14	Acquired	125367	Direct
2017-08-03	Common Stock	S	4250	$155.72	Disposed	121117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-03	Stock Option (Right to Buy)	$109.14	M	4250	Disposed	2025-02-02	Common Stock (4250)	Direct

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.

F2: The option vests in 16 quarterly installments from 2/3/2015.